PDCD1 and lung carcinoma: If NBTXR3 can evoke such consistent abscopal effects in both anti-PD1-sensitive as well as anti-PD1-resistant lung cancers, the probability of using it for the treatment of metastatic lung cancer is high regardless of the sensitivity to immunotherapy [120].